261,741 Shares in Sanofi (NASDAQ:SNY) Bought by Iron Triangle Partners LP

Iron Triangle Partners LP bought a new position in Sanofi (NASDAQ:SNY) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 261,741 shares of the company’s stock, valued at approximately $15,084,000. Sanofi makes up approximately 2.1% of Iron Triangle Partners LP’s portfolio, making the stock its 18th largest holding.

Several other hedge funds also recently made changes to their positions in SNY. Barrow Hanley Mewhinney & Strauss LLC boosted its position in shares of Sanofi by 113.8% during the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock valued at $288,381,000 after buying an additional 3,164,092 shares during the last quarter. Magnetar Financial LLC lifted its position in Sanofi by 1,153.1% during the second quarter. Magnetar Financial LLC now owns 2,506,286 shares of the company’s stock valued at $121,605,000 after purchasing an additional 2,306,286 shares during the period. Jennison Associates LLC boosted its holdings in Sanofi by 938.0% in the third quarter. Jennison Associates LLC now owns 1,904,445 shares of the company’s stock worth $109,753,000 after purchasing an additional 1,720,972 shares during the last quarter. Thrivent Financial for Lutherans raised its stake in Sanofi by 28,890.2% during the 3rd quarter. Thrivent Financial for Lutherans now owns 1,429,219 shares of the company’s stock valued at $82,366,000 after buying an additional 1,424,289 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Sanofi by 19.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock valued at $417,017,000 after buying an additional 1,370,232 shares during the period. 10.04% of the stock is currently owned by institutional investors.

Sanofi Stock Down 1.1 %

NASDAQ:SNY opened at $47.96 on Tuesday. Sanofi has a 1-year low of $45.22 and a 1-year high of $58.97. The company has a 50-day moving average of $52.80 and a 200 day moving average of $52.15. The firm has a market cap of $121.71 billion, a PE ratio of 24.47, a price-to-earnings-growth ratio of 1.23 and a beta of 0.58. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The firm had revenue of $13.44 billion for the quarter, compared to the consensus estimate of $16.59 billion. During the same quarter in the prior year, the company posted $2.55 earnings per share. The company’s revenue for the quarter was up 12.3% compared to the same quarter last year. As a group, research analysts anticipate that Sanofi will post 4.28 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on SNY. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.